Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones
Information source: University of Virginia
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Saline (Drug); Glucagon (Drug); Placebo (Drug); Atenolol (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: University of Virginia Official(s) and/or principal investigator(s): Michael O Thorner, Principal Investigator, Affiliation: University of Virginia
Overall contact: Ralf Nass, MD, Email: rmn9a@virginia.edu
Summary
Glucagon has been used for decades as a test of growth hormone (GH) reserve. The pathway by
which GH is stimulated by glucagon is not established. Acyl ghrelin has been shown to
increase GH levels and to be stimulated by an increase in adrenergic activity. The proposed
study will test the concept that with the fall in blood glucose it is likely that there is a
sympathetic discharge which contributes to the increase in acyl ghrelin and indirectly leads
to the increase in GH and cortisol.
Clinical Details
Official title: Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones
Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
Primary outcome: Circulating acyl-ghrelin concentration after glucagon stimulation with and without beta-adrenergic blockade
Secondary outcome: Association between circulating acyl-ghrelin concentration and GH and cortisol after glucagon administration with and without beta-adrenergic blockade
Detailed description:
Glucagon given to healthy adults in doses of 1-1. 5 mg i. m. has been shown to result in a
peak glucagon level in the circulation after 30 min, followed by an increase in glucose and
insulin levels. The subsequent decline in glucose, insulin and glucagon was followed by an
increase in cortisol and GH. Ghrelin is a 28 amino acid peptide which is released from the
fundus of the stomach, within the oxyntic glands and the small intestine. It circulates in
two major forms, acylated and des-acylated ghrelin. Acylated ghrelin has strong GH-releasing
effects which are mediated via the G-protein coupled ghrelin receptor. The proposed study
will test the concept that with the fall in blood glucose during a glucagon test it is
likely that there is a sympathetic discharge which contributes to the increase in acyl
ghrelin and indirectly leads to the increase in GH and cortisol.
Eligibility
Minimum age: 18 Years.
Maximum age: 30 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
1. Healthy normal men
2. Age 18-30 yrs
3. BMI 18-27 kg/m2
Exclusion Criteria:
1. Medication or previous surgery known to affect ghrelin secretion.
2. Medications known to have an impact on body weight (Seroquel, tricyclic
antidepressants).
3. Medications known to have an impact on the beta adrenergic system.
4. Coronary artery disease, congestive heart failure, peripheral vascular disease,
diabetes mellitus, significant hypertension (BP >180 systolic or >100 diastolic at
rest); renal, hepatic, pulmonary disease; untreated hypothyroidism, untreated
hyperthyroidism; history of seizure disorder; history of malignancy (other than some
skin cancers), history of active chronic infections (e. g., HIV, tuberculosis).
5. Endocrine disorders, i. e., pheochromocytoma, adrenal insufficiency
6. Hematocrit < 41% men
7. History of daily tobacco use within past 3 months
8. Chronic alcohol abuse by history
9. Weight not stable (more than 10% weight change or more over past 6 months)
10. Strenuous exercise for average of more than 60 min/day
11. Investigational drug within past 6 weeks
12. Psychiatric history especially eating disorders
13. Transmeridian travel within 2 weeks prior to or during study
14. Known hypersensitivity to beta-blockers
15. Estimated Glomerular Filtration Rate below 60 mL/min/1. 73m2.
16. Known cardiac dysrhythmia, especially first degree heart block. -
Locations and Contacts
Ralf Nass, MD, Email: rmn9a@virginia.edu
University of Virginia, Charlottesville, Virginia 22902, United States; Recruiting Ralf Nass, MD, Email: rmn9a@virginia.edu Michael O Thorner, Principal Investigator
Additional Information
Starting date: December 2012
Last updated: February 19, 2013
|